LC
EGRX

Lindbrook Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Lindbrook Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-182
Closed -$5.16K – 2875
2023
Q1 		$5.16K Sell
182
-95
-34% -$2.82K ﹤0.01% 1840
2022
Q4 		$8.1K Buy
277
+158
+133% +$5.02K ﹤0.01% 1542
2022
Q3 		$3K Buy
+119
New +$4.37K ﹤0.01% 1955
2021
Q2 		– Sell
-24
Closed -$1K – 2016
2021
Q1 		$1K Hold
24
– – ﹤0.01% 1827
2020
Q4 		$1K Hold
24
– – ﹤0.01% 1727
2020
Q3 		$1K Hold
24
– – ﹤0.01% 1688
2020
Q2 		$1K Hold
24
– – ﹤0.01% 1658
2020
Q1 		$1K Buy
+24
New +$1.2K ﹤0.01% 1605

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's EGRX Position: Q2 2023 in Review

Lindbrook Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 182 shares — an estimated $5.16K sold.

Lindbrook Capital first reported a position in EGRX in Q1 2020 and held it in 8 quarters. The position peaked at $8.1K in Q4 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Lindbrook Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Lindbrook Capital sold 182 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $5.16K.
  • Lindbrook Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 8 quarters.
  • Lindbrook Capital's Eagle Pharmaceuticals, Inc. position peaked at $8.1K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.